The approval of the novel long-acting HIV injection; Cabenuva®- Cabotegravir and 
Rilpivirine injectable formulation) and the recent call by the World Health 
Organization for promoting community-based ART management, underscore the 
remarkable progress towards meeting the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) 95-95-95 targets by 2030. As the availability of 
antiretroviral therapy (ART) for the treatment of HIV/AIDS has increased in 
resource-limited settings, there has been a move to develop and implement 
alternative treatment delivery models such as Differentiated Service Delivery 
(DSD) in high prevalence countries to meet the global targets for HIV treatment 
while maintaining the quality of care. However, there is limited data on the 
involvement of community pharmacies in the delivery of ART within the community. 
Although, in western countries, several studies have documented the different 
roles community pharmacists can play in the management of HIV/AIDS. Community 
pharmacists are the most accessible and first points of health care for most 
clients. They are trusted, highly trained health care professionals. They should 
be incorporated and allowed to administer the Cabenuva® injection if the battle 
against the HIV pandemic is to be totally won. In this paper, we, therefore, aim 
to explore how the community pharmacist can be positioned in HIV service 
delivery regarding the administration of the Novel long-acting Cabenuva® 
injection formulation. It is therefore recommended that the Nigerian government 
embrace community pharmacy-led drug administration initiatives and embark on 
accredited training programmes for the profession in line with drug 
administration services. The government should also put in place necessary 
funding mechanisms for community pharmacists for the extra workload placed on 
them in administering injection drug formulation in their respective pharmacies.